Research Using Biosamples and Subjects from Type 1 Diabetes Clinical Studies Complications (DP3) | RFA DK 15 019

Opportunity Information: Apply for RFA DK 15 019

The grant opportunity titled "Research Using Biosamples and Subjects from Type 1 Diabetes Clinical Studies Complications (DP3)" (Funding Opportunity Number RFA-DK-15-019) is a discretionary NIH research grant designed to support studies focused specifically on complications of type 1 diabetes. The central goal is to encourage investigators to take advantage of existing resources from prior or ongoing type 1 diabetes clinical studies, particularly by using already-enrolled human subjects and/or previously collected biospecimens. In practical terms, the program is aimed at accelerating new discoveries about why complications happen, how they progress, and what factors might predict or influence outcomes, by leveraging the value of well-characterized clinical study cohorts and sample collections rather than starting entirely new cohorts from scratch.

The opportunity sits in NIH's health-related funding portfolio (CFDA 93.847) and is categorized under Food and Nutrition, Health. It uses the grant funding instrument and is labeled with the DP3 mechanism, indicating a targeted program type intended to drive a particular research aim. The FOA was created on October 8, 2015, with an original closing date of March 3, 2016. The posted award ceiling is $1,000,000, which signals that projects were expected to be substantial in scope, potentially involving complex analyses of clinical data, deep phenotyping of complications, advanced laboratory assays on stored biosamples, or follow-on clinical evaluations of participants from legacy studies.

A defining feature of this announcement is the emphasis on "using subjects and/or samples from clinical studies on type 1 diabetes." That phrasing points toward research that is anchored in established clinical-study infrastructures: cohorts with known histories, standardized data collection, and existing consent frameworks, as well as biorepositories containing blood, urine, tissue, DNA, or other materials collected under rigorous protocols. By focusing on these already-developed assets, applicants would be expected to propose efficient, well-justified studies that extract new scientific value from prior investments in type 1 diabetes clinical research, especially around microvascular and macrovascular complications and other long-term outcomes that can be difficult and expensive to study prospectively.

Eligibility is broad and intentionally inclusive. Standard eligible applicants include a wide range of U.S. government entities (state, county, city/township, and special district governments), independent school districts, public housing authorities and Indian housing authorities, federally recognized Native American tribal governments, and Native American tribal organizations that are not federally recognized tribal governments. Academic eligibility includes public and state-controlled institutions of higher education as well as private institutions of higher education. The FOA also allows participation by nonprofit organizations both with and without IRS 501(c)(3) status (as long as they are not institutions of higher education in those categories), and it explicitly includes for-profit organizations (other than small businesses) and small businesses. In addition, the announcement highlights other eligible applicant types such as Alaska Native and Native Hawaiian Serving Institutions, Asian American Native American Pacific Islander Serving Institutions (AANAPISI), Hispanic-serving Institutions, Historically Black Colleges and Universities (HBCUs), Tribally Controlled Colleges and Universities (TCCUs), faith-based or community-based organizations, eligible federal agencies, regional organizations, U.S. territories or possessions, tribal governments other than federally recognized ones, and even non-U.S. entities (foreign organizations). Taken together, that scope suggests NIH wanted to draw proposals from many kinds of institutions, including those serving underserved or underrepresented communities, and also to allow international expertise where it could strengthen the science.

In summary, this FOA is best understood as an NIH-funded push to deepen understanding of type 1 diabetes complications by reusing and reanalyzing high-value human subjects and biospecimen resources from existing clinical studies. It supports applicants across academia, government, nonprofit, and industry, including domestic and foreign organizations, with a relatively high maximum award level that could accommodate multidisciplinary projects. The intent is to generate new insights efficiently by building on established cohorts and sample repositories, rather than recreating them, ultimately helping clarify mechanisms, risk factors, biomarkers, and trajectories of complications in type 1 diabetes.

• The National Institutes of Health in the food and nutrition, health sector is offering a public funding opportunity titled "Research Using Biosamples and Subjects from Type 1 Diabetes Clinical Studies Complications (DP3)" and is now available to receive applicants.
• Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.847.
• This funding opportunity was created on 2015-10-08.
• Applicants must submit their applications by 2016-03-03. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
• Each selected applicant is eligible to receive up to $1,000,000.00 in funding.
• Eligible applicants include: State governments, County governments, City or township governments, Special district governments, Independent school districts, Public and State controlled institutions of higher education, Native American tribal governments (Federally recognized), Public housing authorities/Indian housing authorities, Native American tribal organizations (other than Federally recognized tribal governments), Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education, Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education, Private institutions of higher education, For-profit organizations other than small businesses, Small businesses, Others.

Apply for RFA DK 15 019

[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal: